Lysogene S.A. (LYSGF)
| Previous close | 3.5000 |
| Open | 3.5000 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 3.5000 - 3.5000 |
| 52-week range | 3.5000 - 3.5000 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 60.175M |
| Beta (5Y monthly) | 0.68 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.8480 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Lysogene Releases Results From June 24, 2022, Ordinary and Extraordinary Annual General Meeting
PARIS, June 27, 2022--Regulatory News: Lysogene (Paris:LYS) (FR0013233475 – LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, held its ordinary annual and extraordinary general meeting of shareholders on June 24, 2022, which was chaired by Karen Aiach, Chairman of the Board of directors and chief executive officer.
- Business Wire
Lysogene Provides Clinical Update on AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPS IIIA at the 25th Annual ASGCT Meeting
PARIS, June 03, 2022--Regulatory News: Lysogene (Paris:LYS) (FR0013233475 – LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, provided updated clinical data from the ongoing AAVance phase 2/3 clinical trial with the investigational gene therapy LYS-SAF302 for the treatment of MPS IIIA (NCT03612869) during the 25th Annual Meeting of the ASGCT (American Society for Gene & Cell Therapy) in Washington, DC.
- Business Wire
Lysogene Reports its Cash Position as of 31 March 2022
PARIS, April 28, 2022--Regulatory News: Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today reports its cash position of €10.7 million1 as of 31 March 2022 (compared to €12.3 million as of 31 December 2021).
